

News release 2 November 2015

PHYZAT ANNOUNCES R&D AGREEMENT WITH MEDINUP

Porto, Portugal – Phyzat announced today that it signed with MedinUP an R&D agreement comprising several test activities on Phyzat’s proprietary siRNA compounds within Phyzat’s Primiphy project. The tests will be carried out in MedinUP according to Phyzat’s protocols, for a period of over 1 year.

Paulo Osswald, CFO at Phyzat, commented: “The MedinUP associated laboratories at the University of Porto have a long established expertise in carrying out the *in vitro* and *in vivo* tests included in this program. This agreement allows Phyzat to benefit from that expertise in the validation of specific targets and to substantially shorten this phase of the program, allowing Phyzat to expand internally onto other targets and their gene silencing in difficult to treat medical conditions with high unmet need. We look very much forward to this collaboration and expect it to evolve into follow-up agreements in the continuation of the Primiphy project and other new projects.”

Paulo Correia de Sá, Scientific Board Member at MedinUP, said: “MedinUP’s capacity to translate ground-breaking research into more effective therapies is aligned with the needs and expectations of Phyzat innovative drug discovery programs. Our highly complementary unit combines a basic science approach with clinical expertise to address fundamental questions on human diseases. The collaboration with Phyzat typifies this line of collaborative research which we are strongly committed to develop.

Phyzat is a biopharmaceutical company, incorporated in Porto to develop innovative RNA-based therapeutics with a discovery and clinical development program based on siRNA technologies. The Primiphy project is a discovery and pre-clinical development project of proprietary RNAi based therapeutic solutions.

MedinUP - Center for Drug Development and Innovative Medicine is a research center of fundamental, translational-oriented and clinical pharmacology aimed at the development of better and safer medicines by exploring novel drug targets, unraveling new metabolic pathways and studying their interactions with living systems.

MedinUP is hosted by the University of Porto and based in research laboratories of Pharmacology and Therapeutics (Faculty of Medicine), Pharmacology and Neurobiology (ICBAS), Drug Sciences (Faculty of Pharmacy) and Bone Metabolism and Regeneration (Faculty of Medical Dentistry).

For inquiries contact:

paulo.osswald@phyzat.com